Venture
Tune Therapeutics, Inc.
Latest Form D 2025-01-24- CIK 2053139
- State WA
- Biotechnology
- 1 Form D offering since 2025-01-24
- Total sold
- $182M
- across its one offering
- Rounds
- 1
- Form D offerings since 2025-01-24
- Latest round
- $182M
- 2025-01-24 · 021-536110
- Investors
- 39
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2025-01-24 · $182M
- 2025-01-24$182M021-536110
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($182M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-536110 | First filed2025-01-24 | Latest2025-01-24 | Sought$208M | Sold$182M | Investors39 | Exemptions506(b) |
Who backs Tune Therapeutics, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-01-24
| Name | Relationship |
|---|---|
| Akira Matsuno | RelationshipExecutive Officer |
| Ali Behbahani | RelationshipDirector |
| Charles Gersbach | RelationshipDirector |
| Dan McHugh | RelationshipExecutive Officer, Director |
| John McHutchison | RelationshipDirector |
| Zachary Hale | RelationshipExecutive Officer |
| Derek Jantz | RelationshipExecutive Officer |
| Yuan Zhang | RelationshipExecutive Officer |
| Blythe Sather | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Washington (WA)
- Exemptions
- Rule 506(b)
- First filed
- 2025-01-24
- Latest filing
- 2025-01-24
Who backs Tune Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗